Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
We studied the in vitro and in vivo efficacies of the investigational drug isavuconazole against mucormycosis due to Rhizopus delemar. Isavuconazole was effective, with MIC and minimal fungicidal concentration (MFC) values ranging between 0.125 and 1.00 μg/ml. A high dose of isavuconazole prolonged the survival time and lowered the tissue fungal burden of cyclophosphamide/cortisone acetate-treated mice infected with R. delemar and was as effective as a high-dose liposomal amphotericin B treatment. These results support the further development of this azole against mucormycosis.
The Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, and St. John's Cardiovascular Research Center, Torrance, California, USA.
Guanpingsheng
G
Luo
Teclegiorgis
T
Gebremariam
Hongkyu
H
Lee
John E
JE
Edwards
Laura
L
Kovanda
Ashraf S
AS
Ibrahim
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D007165:Immunosuppression Therapy; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009091:Mucormycosis / Q000517:prevention & control*; D009570:Nitriles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C508735:isavuconazole